
OR WAIT null SECS
Diana Isaacs, PharmD, and Natalie Bellini, DNP, discuss tubeless Mobi's FDA clearance, CVS Caremark's CGM formulary shift, and a transmitter-free implant.
Welcome back to Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives!
The US Food and Drug Administration (FDA) cleared a tubeless cartridge and infusion set for the Tandem Mobi pump on November 12, 2026, adding a third US tubeless automated insulin delivery (AID) system.1 The infusion set is cleared for up to 7 days of wear, the longest of any tubeless AID system, while the cartridge is cleared for 3 days.1
On this episode of Diabetes Dialogue, hosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, also covered a continuous glucose monitor (CGM) formulary change and a transmitter-free implantable sensor.
The new supplies convert the existing Mobi pump rather than replacing it, so users can switch between tubed and tubeless wear on the same device.1 A patient could wear it tubeless on the arm in winter and switch to tubing at a less visible site in summer, a flexibility no competing system offers. Unlike Omnipod 5 and the Beta Bionics Mint, Mobi still requires daily charging.
The main draw is Control-IQ+, cleared for type 1 diabetes in patients aged 2 years and older, adults with type 2 diabetes, and pregnancy complicated by type 1 diabetes. In the 2IQP trial, Control-IQ+ lowered HbA1c by 0.9 percentage points in insulin-treated type 2 diabetes, vs 0.3 points with CGM alone (P < .001).2 In the CIRCUIT trial, pregnant participants using the system spent 65.4% of time in the pregnancy-specific range vs 50.3% with standard care (P < .001).3
Patients on high total daily insulin doses may need site rotation more often than every 7 days to keep absorption consistent and limit lipohypertrophy. Tandem expects a 2027 launch, with tubeless supplies available only through the pharmacy benefit, where Mobi coverage sits near 50%.
Access concerns extend to CGM. Some CVS Caremark and Aetna commercial formularies will switch from exclusive Dexcom to exclusive FreeStyle Libre coverage on January 1, 2027, a notable shift for Mobi users, since the pump pairs only with Dexcom.4 Some practices are issuing 90-day supplies before year end to buy time for prior authorizations.
Senseonics began a first-in-human study in October 2026 of Freedom, a 1-year implantable CGM designed to connect directly with a smartphone without the Eversense 365 on-body transmitter.5 A pivotal trial is planned for 2027, with a potential launch in 2028.5
Collectively, these developments show device makers competing on wear time, form factor, and flexibility, even as payer contracting increasingly shapes which devices reach patients.